Redeye views the RMAT designation from the FDA as a possible game-changer for Immunicum. While the exact implications for the future clinical development are yet to be fully defined, we believe inclusion in this expedited program provides a clear boost to the company ahead of discussions with regulators and potential partners. Our base case is under review for an upgrade.